Amgen exits neuroscience research, cuts 180 US jobs

Amgen is ending most of its neuroscience research, which will result in 180 employees losing their jobs, according to EndPoints News

Most of the job cuts will be in Cambridge, Mass., the hub of Amgen's neuroscience research, but some research and development positions in Thousand Oaks, Calif., and South San Francisco also will be affected. 

Amgen's exit from neuroscience research follows such other industry leaders as GlaxoSmithKline, Pfizer and AstraZeneca, which recently ended their work on neurological diseases.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.